Dr Reddy's launches oral bronchodilator for asthma, COPD
By Our Corporate Bureau | 16 May 2006
Dr Reddy's Laboratories Ltd has announced that it has introduced a European research product Doxofylline, a novel second-generation xanthine bronchodilator, for the first time in India. The company has introduced this product under license agreement from Kent Union Ltd, Hong Kong, and marketing cooperation with Netherlands-based pharma company, Eurodrug Laboratories BV.
Doxofylline has been introduced under the brand name ‘Doxobid’ and the 400mg dosage will be available in a special pack of 10's. Doxobid is meant to treat patients suffering from asthma and/or chronic obstructive pulmonary disease (COPD).
Launched nationwide, Doxobid will further help the Dr Reddy's to consolidate its position in the asthma and COPD segment as it has been moving towards strengthening its respiratory portfolio. The total market of methyl xanthines (combinations and plain) is estimated at around at Rs 60 crore.
Doxofylline has been introduced under the brand name ‘Doxobid’ and the 400mg dosage will be available in a special pack of 10's. Doxobid is meant to treat patients suffering from asthma and/or chronic obstructive pulmonary disease (COPD).
Launched nationwide, Doxobid will further help the Dr Reddy's to consolidate its position in the asthma and COPD segment as it has been moving towards strengthening its respiratory portfolio. The total market of methyl xanthines (combinations and plain) is estimated at around at Rs 60 crore.